Annals of dermatology最新文献

{"title":"Plasma Metabolomics Indicates Potential Biomarkers and Abnormal Metabolic Pathways in Female Melasma Patients.","authors":"Xiaoli Zhang, Yi Chen, Hedan Yang, Hui Ding, Pingping Cai, Yiping Ge, Huiying Zheng, Xiaojie Sun, Yin Yang, Xinyu Li, Tong Lin","doi":"10.5021/ad.23.141","DOIUrl":"10.5021/ad.23.141","url":null,"abstract":"<p><strong>Background: </strong>Melasma is a common and chronic pigmentary disorder with complex pathogenesis, and the relationship between melasma and metabolic syndrome remains elusive. Thus, metabolomics might contribute to the early detection of potential metabolic abnormalities in individuals with melasma.</p><p><strong>Objective: </strong>The present study aims to analyze changes in plasma metabolites of female melasma patients and identify disease markers as well as explore potential therapeutic targets.</p><p><strong>Methods: </strong>Plasma samples from 20 female patients with melasma and 21 healthy female controls that were comparable in terms of age and body mass index were collected for untargeted metabolomics investigations. Ultra-high performance liquid chromatography-mass spectrometry was used to analyze metabolites in the plasma. Metabolic pathway analyses were employed to identify significantly differentially expressed metabolites in melasma patients. Receiver operating characteristic curves were constructed, and correlation analyses were performed using the modified Melasma Area and Severity Index and oxidative stress levels.</p><p><strong>Results: </strong>In contrast to healthy subjects, melasma patients showed significant alterations in 125 plasma metabolites, including amino acids, lipids, and carbohydrate-related metabolites. KEGG pathway analysis suggested that primary pathways associated with the development of melasma include tryptophan metabolism, as well as the biosynthesis of phenylalanine, tyrosine, and tryptophan. Importantly, based on receiver operating characteristic curves and correlation analyses, several metabolites were identified as robust biomarkers for melasma.</p><p><strong>Conclusion: </strong>Collectively, this study identified significant changes in plasma metabolites in melasma patients, providing new insights into the pathogenesis of melasma and opening novel therapeutic avenues.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 5","pages":"300-309"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Affecting the Response and Patient Satisfaction of Topical Immunotherapy in Alopecia Areata: A Nationwide Study.","authors":"Young Lee, Kyungmin Kim, Bark-Lynn Lew, Chang-Hun Huh, Hoon Kang, Yong Hyun Jang, Do Young Kim, Hyun-Tae Shin, Moon-Bum Kim, Jin Park, Min Sung Kim, Gwang Seong Choi","doi":"10.5021/ad.23.138","DOIUrl":"10.5021/ad.23.138","url":null,"abstract":"<p><strong>Background: </strong>Contact immunotherapy using diphenylcyclopropenone (DPCP) is a recommended treatment for severe alopecia areata (AA); however, few clinical factors are known, and few standardized application methods affecting therapeutic efficacy have been devised.</p><p><strong>Objective: </strong>To confirm the therapeutic response of DPCP immunotherapy in AA, first we analyze the factors influencing its outcome and patient satisfaction levels, after which we standardize the DPCP treatment method for better outcomes.</p><p><strong>Methods: </strong>We utilized a nationwide questionnaire-based survey to assess patient satisfaction and undertook a medical record review involving 412 patients currently undergoing treatment for DPCP.</p><p><strong>Results: </strong>The patients' mean age was 36.4 years, and 27% of the cases were diagnosed as AA in childhood. Treatment response was higher when DPCP was used to treat the entire scalp, including subclinical lesions, and longer treatment durations and longer intervals between treatments were associated with a better treatment response. Atopy (atopic dermatitis, allergic rhinitis and bronchial asthma), thyroid disorder, and extent of hair loss were all negatively correlated with the treatment response. However, there was no correlation between the treatment response and factors such as the age of onset, a family history of AA, nail changes, or AA duration, which are commonly known to be associated with a poor prognosis.</p><p><strong>Conclusion: </strong>DPCP immunotherapy is an effective treatment for AA, and the study demonstrated the factors affecting DPCP treatment response and patients' satisfaction and may contribute to standardizing the DPCP treatment method for better outcomes.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"225-230"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nail Psoriasis: Clinical Features and Severity Assessment.","authors":"Sang Woong Youn","doi":"10.5021/ad.24.026","DOIUrl":"10.5021/ad.24.026","url":null,"abstract":"<p><p>The nail is an important characteristic in the context of psoriasis. Nail psoriasis exhibits several clinical manifestations. Since the development of the Nail Psoriasis Severity Index (NAPSI) score assessment tool for evaluating the severity of nail psoriasis, nail matrix symptoms such as pitting, leukonychia, crumbling, and red spots have been observed in the lunula. Nail bed symptoms include onycholysis, subungual hyperkeratosis, oil spots, and splinter hemorrhage. However, Beau's lines and nail fold psoriasis, which are not included in this assessment tool, should be considered essential symptoms for indicating the activity of nail psoriasis. Although NAPSI is the most widely used tool for assessing the severity of nail psoriasis, it has uncontrolled limitations. Although other assessment tools have been developed, none have successfully replaced the NAPSI. In clinical trials for nail psoriasis, the NAPSI is used in various forms, such as improvement rates, changes in the mean NAPSI score, and achievement rates of NAPSI 75. Consequently, caution is warranted when interpreting the clinical trial results related to nail psoriasis improvement.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"191-196"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Up-and-Coming Drugs for the Treatment of Vitiligo.","authors":"Seol Hwa Seong, Sang Ho Oh","doi":"10.5021/ad.24.038","DOIUrl":"10.5021/ad.24.038","url":null,"abstract":"<p><p>Vitiligo is a chronic autoimmune disease that causes depigmented patches on the skin. It affects 0.5%-2.0% of the global population. It goes beyond physical appearance, often leading to stigmatization, low self-esteem, and depression, burdening patients with psychosocial challenges. The pathogenesis of vitiligo involves the loss of melanocytes due to autoreactive CD8+ T cells, triggered by environmental stressors and exacerbated by cellular vulnerabilities and immune responses. The release of danger signals and pro-inflammatory factors initiates an immune cascade perpetuating melanocyte destruction, mainly driven by interferon-γ and the C-X-C motif chemokine ligand 9/10-chemokine receptor 3 axis. Long-lasting tissue-resident memory T cells (Trms) and cytokines contribute to lesion persistence. Current treatments focus on topical steroids and tacrolimus, systemic steroids, and phototherapies, but their efficacy remains suboptimal, necessitating the development of new therapeutic options. Building on recent advancements in understanding the immunological mechanisms in vitiligo pathogenesis, with the initiation of Food and Drug Administration approval of topical ruxolitinib, various potential treatment options such as JAK inhibitors, cytokine blockers, and Trm or regulatory T cell targeting agents are being clinically researched and anticipated for vitiligo based on both preclinical and clinical data. This review aims to categorize and summarize the diverse investigational drugs currently undergoing clinical trials for vitiligo. By examining clinical outcomes, it is anticipated that this review will bring hope to dermatologists and patients regarding vitiligo, a condition that has historically posed challenges and transform it into a realm of potential possibilities.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"197-208"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intralesional Methotrexate Injection for the Treatment of Epithelial Crateriform Tumor.","authors":"Jun Hyuk Cho, Hyun Mo Lee, Yoon Jae Kim, Dai Hyun Kim, Hyo Hyun Ahn, Soo Hong Seo","doi":"10.5021/ad.23.135","DOIUrl":"10.5021/ad.23.135","url":null,"abstract":"<p><strong>Background: </strong>Intralesional methotrexate injection (IL-MTX) is an appropriate strategy for treating epithelial crateriform tumors (ECTs) when surgical excision can result in functional or cosmetic defects; however, not all ECTs are responsive to this treatment.</p><p><strong>Objective: </strong>This study aimed to evaluate the effectiveness of IL-MTX for ECTs and to determine the differences in clinical response according to the pathological features.</p><p><strong>Methods: </strong>The medical records of patients treated with IL-MTX for their ECTs were retrospectively reviewed. Effectiveness was evaluated in terms of size reduction and flattening.</p><p><strong>Results: </strong>Twenty-five cases of ECTs with biopsy were included in this study. Eight cases of keratoacanthoma (KA) and 15 cases of squamous cell carcinoma (SCC) were identified, but 2 cases could not be clearly distinguished. Seventeen patients (68%) showed a response after injection, and response rate in KA and SCC were 75% (6/8) and 60% (9/15), respectively. Nine patients showed complete resolution with IL-MTX. Patients received 3 injections, and regression was observed in 7.56 weeks after the first injection. According to histopathological results, patients with KA and SCC received 2 and 3.33 injections, respectively, and complete resolution was observed after 7 and 7.67 weeks, respectively.</p><p><strong>Conclusion: </strong>IL-MTX is safe and effective, and could be considered as a useful non-surgical treatment option for ECTs. Both KA and crateriform SCC showed good response; However, KA showed a better response.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"209-214"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Review of Scoring Systems for Hidradenitis Suppurativa.","authors":"Youngbeom Kim, Jungsoo Lee, Hoon-Soo Ki, Hyun-Chang Ko, Byung-Soo Kim, Moon-Bum Kim, Kihyuk Shin","doi":"10.5021/ad.36.001","DOIUrl":"10.5021/ad.36.001","url":null,"abstract":"","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"255"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Serum Zonulin Levels in Individuals Diagnosed With Chronic Spontaneous Urticaria.","authors":"Alkım Ünal, Gözde Ülfer","doi":"10.5021/ad.24.020","DOIUrl":"10.5021/ad.24.020","url":null,"abstract":"<p><strong>Background: </strong>There have been reports indicating a correlation between heightened intestinal permeability and many autoimmune and chronic inflammatory disorders. The involvement of autoimmunity is now recognized as a significant factor in the development of chronic spontaneous urticaria (CSU). Zonulin is an important biomarker that regulates tight junction permeability within cells in the gastrointestinal tract, hence facilitating intestinal permeability.</p><p><strong>Objective: </strong>To evaluate the correlation of CSU with intestinal permeability by measuring the serum levels of zonulin in patients diagnosed with CSU.</p><p><strong>Methods: </strong>The study included 60 patients diagnosed with CSU and 64 age- and sex-matched healthy individuals as controls. Levels of serum zonulin were determined using the ELISA method.</p><p><strong>Results: </strong>Although the serum zonulin value of the patients was higher compared to the controls, the difference did not reach a significant level (24.65±8.49 ng/ml vs. 21.03±7.36 ng/ml, <i>p</i>=0.077). The serum zonulin level had a significant correlation with the urticaria activity score in the CSU group (<i>p</i>=0.013). The results of the current study revealed that serum zonulin values significantly differed between patients with CSU and healthy controls.</p><p><strong>Conclusion: </strong>This study is important in terms of being the first to investigate the serum zonulin levels in CSU. However, there is a need for further studies with larger patient groups.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"231-235"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term Safety of Dimethyl Fumarate for Psoriasis in Korea.","authors":"Tae Min Kim, Seong Jin Jo","doi":"10.5021/ad.23.054","DOIUrl":"10.5021/ad.23.054","url":null,"abstract":"","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"252-254"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomaterial Stiffness of Wharton's Jelly-Derived Mesenchymal Stem Cell-Conditioned Medium Modulates Fibroblasts Proliferation and Migration: A Preliminary Study.","authors":"Sangmin Choi, Jaeyun Kim, Soyul Kim, Yoonsung Lee, Man S Kim, Bark-Lynn Lew, Soon-Hyo Kwon","doi":"10.5021/ad.23.048","DOIUrl":"10.5021/ad.23.048","url":null,"abstract":"","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"247-251"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities.","authors":"Ju Yeop Shin, DongHoon Han, Ki Young Yoon, Do Hyeon Jeong, Yong Il Park","doi":"10.5021/ad.23.136","DOIUrl":"10.5021/ad.23.136","url":null,"abstract":"<p><strong>Background: </strong>Anti-aging products are widely used, but the desire for safe and more efficient anti-aging products continues to increase. Dissolving microneedle patches (MNPs) have provided a more efficient transdermal drug delivery solution. MNP is a promising candidate for developing better anti-aging products.</p><p><strong>Objective: </strong>To develop a more efficient anti-aging MNP product, we fabricated a dual anti-wrinkle microneedle patch (named DA-MNP) using droplet extension (DEN^®) technology and evaluated its skin puncture ability, safety, and efficacy through clinical studies.</p><p><strong>Methods: </strong>A DA-MNP comprising hyaluronic acid (HA) polymer backbone, acetyl octapeptide-3, and L-ascorbic acid 2-glucoside and sodium cyclic lysophosphatidic acid was fabricated using DEN^® technology. Placebo MNPs comprising only HA were also fabricated. Twenty-four healthy subjects were enrolled in this comparative clinical study. The DA-MNP or placebo MNP was separately applied to the left and right eyes of subjects for overnight. Assessments, including wrinkle improvement, trans-epidermal water loss (TEWL), eye lifting and adverse effects were evaluated at each scheduled visit day for 28 days.</p><p><strong>Results: </strong>The DA-MNP showed mechanical strength enough for puncturing the stratum corneum. Compared to placebo MNP group, the DA-MNP treated group showed an effective eye wrinkles improvement and better anti-aging of skin, with reduced TEWL, enhanced skin elasticity and lifting, and no adverse effects.</p><p><strong>Conclusion: </strong>The present study demonstrated that the fabricated DA-MNP exhibited fast acting on deep wrinkles and enhanced anti-aging efficacy, with no skin safety concern. Thus, this DA-MNP may serve as a new transdermal delivery solution for skin wrinkling and aging.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"215-224"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}